Jordan A
Division of Metabolism and Endocrine Drug Products, United States Food and Drug Administration.
Contraception. 1994 Mar;49(3):189-201. doi: 10.1016/0010-7824(94)90037-x.
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys. It has been examined for its effects on reproduction in mice, rats, and rabbits, and for carcinogenic potential in rats, mice, beagle dogs, and rhesus monkeys. Genotoxicity tests have been performed in vitro and in vivo. This paper describes the toxicology data submitted to the US FDA in support of the New Drug Application (NDA) for Depo-Provera as well as data published in the literature. When interpreted in the light of the available pharmacokinetic information, these data demonstrate that DMPA is not significantly different from other contraceptive progestogens in its toxic and tumorigenic potential.
醋酸甲羟孕酮长效注射剂(Depo - Provera,即醋酸甲羟孕酮长效注射液或DMPA),通过皮下或肌肉注射给药,已在多种动物物种中进行了全面的毒理学评估。DMPA已在啮齿动物、兔子和猴子身上进行了短期和长期毒性研究。它已被检测对小鼠、大鼠和兔子生殖的影响,以及对大鼠、小鼠、比格犬和恒河猴的致癌潜力。已进行了体外和体内遗传毒性试验。本文描述了提交给美国食品药品监督管理局(FDA)以支持醋酸甲羟孕酮长效注射剂新药申请(NDA)的毒理学数据以及文献中发表的数据。根据现有的药代动力学信息进行解读时,这些数据表明DMPA在毒性和致瘤潜力方面与其他避孕孕激素没有显著差异。